ROCO
1780
Market cap73mUSD
Jul 09, Last price
24.70TWD
1D
0.00%
1Q
-7.49%
Jan 2017
33.51%
IPO
58.64%
Name
Allied Biotech Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Allied Biotech Corporation operates as a global producer and supplier specializing in carotenoids. The company's diverse product portfolio features key carotenoids such as: Beta-Carotene, known for imparting vibrant yellow to reddish-orange hues across numerous applications. Beta-Apo-8'-Carotenal, a versatile food colorant delivering shades from rich orange to deep red. Lycopene, a valuable nutrient that provides striking red tones for incorporation into food, dietary supplements, and pharmaceutical formulations. Canthaxanthin, which contributes reddish-orange colors specifically to food and beverage products. Lutein, another carotenoid frequently derived from or associated with green leafy vegetables (like spinach, kale, and broccoli) and egg yolks. Additionally, Allied Biotech offers Nano Coenzyme Q10, an antioxidant crucial for cellular energy production. The corporation caters to a diverse clientele across the food, beverage, dietary supplement, and animal feed sectors. Established in 2001, Allied Biotech Corporation maintains its headquarters in Taipei, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||